Thomas Shiovitz
Psychiatry · Sherman Oaks, CANPI 1942309851
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $144,601 of the $150,835 with a category attached, or 95.9%. Biohaven Pharmaceuticals, Inc. accounts for 60.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $91,580 and has fallen 99.6% since, to $366 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $1436.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$92K
- Biohaven Pharmaceutical Holding Company Ltd.$53K
- Sage Therapeutics, LLC$2K
- Merck$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Boehringer Ingelheim$574
- plus $978 from 9 others
Across 562 payments — averaging $15,577 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.5M
- Biogen$1.9M
- Genentech, Inc.$558K
- Sage Therapeutics, LLC$532K
- AbbVie$488K
- Novartis$450K
- plus $1.3M from 11 others
What the payments were for
- Consulting fees$144,60196%
- Travel & lodging$3,7052%
- Food & beverage$2,5292%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 21 | $91,580 |
| Biohaven Pharmaceutical Holding Company Ltd. | 28 | $52,681 |
| Sage Therapeutics, LLC | 13 | $1,960 |
| Merck | 13 | $1,536 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,526 |
| Boehringer Ingelheim | 4 | $574 |
| Biogen | 4 | $480 |
| Vanda Pharmaceuticals Inc. | 3 | $87 |
| Lundbeck LLC | 4 | $82 |
| F. Hoffmann-la Roche AG | 1 | $80 |
| Sunovion Pharmaceuticals Inc. | 3 | $67 |
| Johnson & Johnson | 3 | $67 |
| AbbVie(2 entities) | 3 | $64 |
| Novartis | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,144
- ADUHELM$235
How this compares
$150,835 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 11 | $189 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Sherman Oaks
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.